Dr. Nikiforow is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
450 Brookline Ave
Dana Farber Cancer Center - Smith 353
Boston, MA 02215Phone+1 617-632-3779Fax+1 617-632-5822
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2010 - 2013
Yale-New Haven Medical CenterResidency, Internal Medicine, 2005 - 2008
Yale School of MedicineClass of 2005
Certifications & Licensure
MA State Medical License 2010 - 2026
CT State Medical License 2008 - 2010- American Board of Internal Medicine Hematology
Clinical Trials
- A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Emapalumab in Adult Patients With HLH Start of enrollment: 2020 Jun 02
Publications & Presentations
PubMed
- 3 citationsPhase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37+ lymphoid malignancies.Matthew J Frigault, Charlotte E Graham, Trisha R Berger, Julie Ritchey, Nora K Horick
Blood. 2024-09-12 - 1 citationsActive infection at the time of CD34+ selected stem cell boost is associated with treatment failure and poor overall survival.Roman M Shapiro, Haesook T Kim, Remy Dulery, Deborah Liney, Heather M Garrity
Blood Advances. 2024-09-10 - 1 citationsACT To Sustain: Adoptive Cell Therapy To Sustain Access to Non-Commercialized Genetically Modified Cell Therapies.Rebecca A Gardner, Claire White, Magdi Elsallab, Stephanie Farnia, Ellen Fraint
Transplantation and Cellular Therapy. 2024-08-01
Journal Articles
- Clinical Predictors of Neurotoxicity After Chimeric Antigen Receptor T-cell TherapySarah Nikiforow, Caron Jacobson, JAMA Neurology
Abstracts/Posters
- A Phase 1 Dose-Escalation Study of Adding Venetoclax to a Reduced Intensity Conditioning (RIC) Regimen Prior to Allogeneic Hematopoietic Cell Transplantation for Patie...Sarah Nikiforow, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Children and Young Adults with Acute Lymphoblastic Leukemia (ALL): Real World E...Sarah Nikiforow, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Anti-CD6 Monoclonal Antibody Itolizumab Efficiently Inhibits T Cell Proliferation after in Vitro TCR Stimulation in the Setting of Acute Graft Versus Host DiseaseSarah Nikiforow, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Press Mentions
Repertoire Immune Medicines and Dana-Farber Cancer Institute Collaborate to Identify Novel Antigen Targets Within HPV+ Head and Neck CancersFebruary 11th, 2021
Atara Biotherapeutics Announces Two Presentations at 59th American Society of Hematology Annual Meeting, Including Positive Interim Results from a Multicenter Expanded Access Study of ATA129 for Patients with Epstein-Barr Virus (EBV)-Associated CancersNovember 1st, 2017
The Fantastic Voyage of a Bag of Cells Shipped West to Be Trained in the Art of Killing CancerOctober 27th, 2017
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
